2026-04-18T07:40:13Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1777532025-12-05T09:22:38Zcom_2072_1057col_2072_478799col_2072_478917

00925njm 22002777a 4500 dc Blecua, Pedro author Martinez-Verbo, Laura author Esteller, Manel author 2021-05-27T15:42:55Z 2021-05-27T15:42:55Z 2020-08-01 2021-05-27T15:42:56Z The rapid advances in high-throughput sequencing technologies have made it more evident that epigenetic modifications orchestrate a plethora of complex biological processes. During the last decade, we have gained significant knowledge about a wide range of epigenetic changes that crucially contribute to some of the most aggressive forms of leukemia, lymphoma and myelodysplastic syndromes. DNA methylation is a key epigenetic player in the abnormal initiation, development and progression of these malignancies, often acting in synergy with other epigenetic alterations. It also contributes to the acquisition of drug resistance. In this review, we summarize the role of DNA methylation in hematological malignancies described in the current literature. We discuss in detail the dual role of DNA methylation in normal and aberrant hematopoiesis, as well as the involvement of this type of epigenetic change in other aspects of the disease. Finally, we present a comprehensive overview of the main clinical implications, including a discussion of the therapeutic strategies that regulate or reverse aberrant DNA methylation patterns in hematological malignancies, including their combination with (chemo-) immunotherapy. Càncer Epigenètica Hematologia Leucèmia Limfomes Metilació Cancer Epigenetics Hematology Leukemia Lymphomas Methylation The DNA methylation landscape of hematological malignancies: an update